Navigation Links
Spectrum Health to offer implantable neurostimulator for hard-to-treat epilepsy patients
Date:12/11/2013

GRAND RAPIDS, Mich., December 10, 2013 Spectrum Health will be the first health system in West Michigan and among the first in the nation to offer treatment with a newly FDA-approved device that uses electric stimulation of the brain for adult epilepsy patients whose seizures have not responded to medication.

The NeuroPace Responsive Neurostimulation (RNS) System is an implantable therapeutic device designed to detect abnormal electrical activity in the brain and respond by delivering imperceptible electrical stimulation to normalize brain activity before an individual experiences seizures.

"For patients with frequent and disabling partial onset seizures who have proven unresponsive to two or more medications and who are not candidates for actual removal of abnormal tissue, this may prove to be a viable and welcome treatment option," said Kost Elisevich, MD, PhD, neurosurgeon, co-chair department of clinical neurosciences, chief, division of neurosurgery, Spectrum Health Medical Group.

The RNS System is designed for use in combination with other therapies in reducing the frequency of seizures in individuals 18 years of age or older. It is indicated for use in patients with partial onset seizures seizures that originate and remain in a limited area of the brain. To be eligible for the procedure, patients must have frequent and disabling seizures (motor partial seizures, complex partial seizures and/or secondarily generalized seizures), whose origin is limited to two or fewer locations in the brain.

NeuroPace, Inc. estimates that approximately 400,000 people in the U.S. meet these criteria and may benefit from treatment with the RNS System.

"Neurostimulation could provide relief from seizures for many patients who are not good candidates for surgery," said Brien Smith, MD, co-chair, department of clinical neurosciences, chief, division of neurology, Spectrum Health Medical Group, and immediate past chair of the National Epilepsy Foundation. "We plan to offer this treatment to eligible patients as soon as it becomes available."

The U.S. Food and Drug Administration (FDA) granted premarket approval for the RNS System on November 14. While employed at Henry Ford Health System, Drs. Elisevich and Smith were one of the first clinical teams in the nation to participate in clinical trials using the RNS System. The device has been evaluated for more than eight years in three clinical trials at 32 comprehensive epilepsy centers in the U.S., including a prospective, randomized, double-blinded, sham stimulation controlled pivotal study.

The pivotal study demonstrated a nearly 38 percent reduction in seizure frequency in patients treated with responsive stimulation compared to an approximately 17 percent reduction in patients who were implanted with the device but were not receiving responsive stimulation during a three month blinded period. In a two-year follow-up phase, 55 percent of the subjects experienced a 50 percent or greater reduction in seizures.

Treatment with the RNS System will take place in Level 4 epilepsy centers throughout the nation following site qualification and physician training. Spectrum Health is the first epilepsy program in West Michigan to receive a Level 4 designation by the National Association of Epilepsy Centers (NAEC). Level 4 centers have the professional expertise and facilities to provide the highest level of medical and surgical epilepsy evaluation and treatment for patients with epilepsy.


'/>"/>

Contact: Tim Hawkins
timothy.hawkins@spectrumhealth.org
616-486-6091
Spectrum Health
Source:Eurekalert

Related biology news :

1. DNA SPECTRUM LAUNCHES GROUNDBREAKING DNA STORAGE PRODUCT
2. Changes to symptom structure in DSM-5 support diagnosis of toddlers with autism spectrum disorder
3. Toward broad-spectrum antiviral drugs for common cold and other infections
4. Study reveals how common gene mutation affects kids with autism spectrum disorders
5. Can videogaming benefit young people with autism spectrum disorder?
6. Gene mutation identified as contributor to autism spectrum disorders
7. Official opening of wildlife health genetic and forensic laboratory between EcoHealth Alliance and Sabah Wildlife Department
8. Reproductive Health Matters announces publication of its latest themed issue: New development paradigm
9. Feeding by tourists compromises health of already-endangered iguanas, study finds
10. UCSB researcher shows microplastic transfers chemicals, impacting health
11. Organovo to Present at the 24th Annual Oppenheimer Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2016)... , Nov. 15, 2016  Synthetic Biologics, ... developing therapeutics focused on the gut microbiome, today ... of 25,000,000 shares of its common stock and ... stock at a price to the public of ... to Synthetic Biologics from the offering, excluding the ...
(Date:11/14/2016)... 14, 2016  xG Technology, Inc. ("xG" or the ... wireless communications for use in challenging operating environments, announced ... 2016. Management will hold a conference call to discuss ... Eastern Time (details below). Key Recent Accomplishments ... million binding agreement to acquire Vislink Communication Systems. The ...
(Date:6/27/2016)... , June 27, 2016 Research and Markets ... America 2016-2020" report to their offering. ... North America to grow at a CAGR of 12.28% ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... This report analyzes the worldwide markets for Biostimulants ... Amino, & Fulvic), Extract Based, and Others. The report also ... & Turf, Row Crops, and Others. The report provides separate ... Japan , Europe , ... , and Rest of World. Annual estimates and forecasts are ...
(Date:12/8/2016)... PA (PRWEB) , ... December 08, 2016 , ... ... engagement platforms, the business of innovation is taking over sports. On Thursday, December ... will explore how technology is disrupting the playing field at a Smart Talk ...
(Date:12/8/2016)... SAN DIEGO , Dec. 8, 2016 /PRNewswire-USNewswire/ ... treatments for congestive heart failure and type 2 ... license for a novel adeno-associated virus (AAV) vector ... Kay , M.D., Ph.D., at Stanford University. The ... of its paracrine gene therapy product pipeline. ...
(Date:12/8/2016)... Portland, Oregon (PRWEB) , ... December 08, 2016 ... ... modules and the FrontPanel SDK that provide essential device-to-computer interconnect using USB or ... do not require FrontPanel support. The FOMD-ACV-A4 is a small, thin, SODIMM-style module ...
Breaking Biology Technology: